SCHEMBL736590

SCHEMBL736590

O=CCCNC(=O)OCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
HTT P42858 1/20 0.63
TGM2 P21980 1/20 0.59
L3MBTL1 Q9Y468 2/20 0.55
KEAP1 Q14145 2/20 0.55
NFE2L2 Q16236 2/20 0.55
MAPT P10636 1/20 0.53
SLC1A3 P43003 1/20 0.52
SLC1A1 P43005 1/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
KAT2B Q92831 1/20 0.49
GAA P10253 1/20 0.49
IDO1 P14902 1/20 0.49
TDO2 P48775 1/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propionaldehyde SCHEMBL3691420 0.92 LMNA (0.57) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL30869144 0.92 HTT (0.58) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL735886 0.91 HTT (0.68) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL23120177 0.90 L3MBTL1 (0.62) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL13055383 0.90 LMNA (0.80) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL3725943 0.89 HTT (0.67) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL7407279 0.89 LMNA (0.65) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL5019074 0.88 LMNA (0.73) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL8988858 0.88 TGM2 (0.69) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL8811162 0.88 TGM2 (0.69) LMNASMN1; SMN2HTTTGM2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200165640-A1 FRUCTOSE-6-PHOSPHATE ALDOLASE VARIANTS FOR ALDOL CARBOLIGATIONS SUSTAINABLE MOMENTUM, S.L. (ES) 2020-05-28 US claimed
CN-110945122-A Fructose-6-phosphate aldolase variants for aldol condensation carbon linking 西班牙高等科研理事会 2020-03-31 CN claimed
EP-3610011-A1 FRUCTOSE-6-PHOSPHATE ALDOLASE VARIANTS FOR ALDOL CARBOLIGATIONS Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2020-02-19 EP claimed
WO-2018189026-A1 FRUCTOSE-6-PHOSPHATE ALDOLASE VARIANTS FOR ALDOL CARBOLIGATIONS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2018-10-18 WO claimed
EP-3388518-A1 FRUCTOSE-6-PHOSPHATE ALDOLASE VARIANTS FOR ALDOL CARBOLIGATIONS Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2018-10-17 EP claimed
US-8288132-B2 Chemoenzymatic process for the preparation of iminocyclitols CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2012-10-16 US claimed
EP-2185713-A2 PROCESS FOR PREPARING CHIRAL COMPOUNDS Pfizer Products Inc. (US) 2010-05-19 EP claimed
EP-2061892-B1 CHEMOENZYMATIC PROCESS FOR THE PREPARATION OF IMINOCYCLITOLS CONSEJO SUPERIOR INVESTIGACION (ES) 2010-02-03 EP claimed
US-20100009417-A1 Chemoenzymatic process for the preparation of iminocyclitols CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2010-01-14 US claimed
EP-2061892-A1 CHEMOENZYMATIC PROCESS FOR THE PREPARATION OF IMINOCYCLITOLS Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2009-05-27 EP claimed
WO-2009019561-A2 PROCESS FOR PREPARING CHIRAL COMPOUNDS PFIZER PRODUCTS INC. (US) 2009-02-12 WO claimed
WO-2008025826-A1 CHEMOENZYMATIC PROCESS FOR THE PREPARATION OF IMINOCYCLITOLS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2008-03-06 WO claimed
EP-1893767-A1 PROCESS FOR PRODUCING ATORVASTATIN, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND INTERMEDIATES THEREOF Pfizer, Inc. (US) 2008-03-05 EP claimed
WO-2006134482-A1 PROCESS FOR PRODUCING ATORVASTATIN, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND INTERMEDIATES THEREOF PFIZER INC. (US) 2006-12-21 WO claimed
EP-3364967-B1 FERROPORTIN INHIBITORS VIFOR INT AG (CH) 2026-05-20 EP disclosed
US-20260124205-A1 MODULATORS OF BETA CATENIN AND USES THEREOF DEWPOINT THERAPEUTICS INC (US) 2026-05-07 US disclosed
WO-2026090104-A1 MODULATORS OF BETA CATENIN AND USES THEREOF DEWPOINT THERAPEUTICS, INC. (US) 2026-04-30 WO disclosed
EP-0297496-A2 Novel process for the preparation of 6,7-Diacyl-7-deacetylforskolin derivatives NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1989-01-04 EP disclosed
US-4795809-A CLAVULANIC ACID INTERMEDIATE BEECHAM GROUP PLC (GB) 1989-01-03 US disclosed
EP-0213914-A2 Clavam derivatives, preparation and intermediates therefor BEECHAM GROUP PLC (GB) 1987-03-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124205-A1 MODULATORS OF BETA CATENIN AND USES THEREOF CTNNB1, CTNNA1, CTNND1 LMNA 275/4885SMN1; SMN2 2898/4885HTT 3044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.